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Abstract: Fludarabine is an inhibitor of DNA/RNA synthesis with antitumor activity on lymphoproliferative malignancies. We
investigated the dose-dependent cytotoxic effects of the drug on human peripheral blood mononuclear cells, the HL60 cell line and
the differentiated HL60 cells. Dimethylformamide was used for the neutrophilic differentiation of HL60 cells and the MTT assay was
used to estimate drug cytotoxicity. Undifferentiated tumor cells had higher proliferation rates compared to the differentiated subline.
There was 57% cell death in HL60 cells at a dose of 5 µg/ml of the drug. On the other hand, in differentiated HL60 cells and
nonmalignant cells, cell death did not exceed 40% after exposure to 500 µg/ml. These results demonstrated that proliferation rate
and differentiation status may have a contribution in fludarabine cytotoxicity.
Key Words: HL60, MTT assay, fludarabine, cytotoxicity, differentiation.

Introduction
Fludarabine (9-β-D-arabinofuranosyl-2-fluoroadenine
monophosphate, F-ara-AMP) is a purine nucleoside
analogue effective in various lymphoproliferative
disorders, in particular chronic lymphocytic leukemia
(CLL). It is dephosphorylated to F-ara-A, which enters the
cell by active transport and then accumulates as the 5’triphosphate, F-ara-ATP (1-3). This active metabolite has
been shown to inhibit DNA synthesis by inhibiting
ribonucleotide reductase, DNA polymerase, DNA primase
and DNA ligase. Thus, incorporation of fludarabine
nucleotides into DNA in proliferating cells highly
correlates with drug induced cell death (4-7).
Termination of RNA chain elongation and inihibition of
RNA synthesis is a unique feature of the drug that may be
important for cytotoxicity on non-dividing cells (8,9). In
additon, recent studies have suggested that fludarabineinduced cytotoxicity observed in quiescent cells, such as
CLL, may be related to caspase activation (10,11). Cell
specificity of the fludarabine has been attributed either to

selective transport into leukemic lymphocytes or to
enhanced phosphorylation to the active form in these cells
(12).
There is an inverse relationship between proliferation
and maturation (13,14). That is, cells lose their
proliferative capacity before or while acquiring the
mature phenotype. Human leukemia cell line HL60 can be
induced to differentiate to mature myeloid phenotype by
a variety of agents (15,16). For example, cells exposed to
dimethylformamide acquire the features of a mature
neutrophil. The present study compared dose-dependent
effects of fludarabine between normal myeloid cells,
leukemic cell line (HL60) and differentiated HL60 cells.
Materials and Methods
Cell Culture
Peripheral mononuclear cells were isolated from a
healthy donor by Ficoll-Hypaque density gradient and
cultured immediately at a concentration of 4 x 106
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cells/ml in RPMI 1640 culture medium supplemented
with 10% heat-inactivated fetal bovine serum, 2 mM Lglutamine, 100 IU/ml penicillin and 100 µg/ml
streptomycin at 37 °C in a humidified incubator
containing 5% CO2 . HL60 cells (human promyelocytic cell
line) were maintained under the same conditions at a
density of 4 x 105 cells/ml. For inducing differentiation,
HL60 cells were cultured in RPMI 1640 (without phenol
red) supplemented with 20% heat-inactivated fetal
bovine serum, 2 mM L-glutamine, 100 IU/ml penicillin
and 100 µg/ml streptomycin. These cells were treated
with 100 mM dimethylformamide for 5 days.
Differentiated HL60 cells were then cultured under the
same conditions as parental HL60 cells at a density of 8 x
105 cells/ml and cytotoxicity was evaluated on the same
day. Proliferation rates of parental and differentiated
HL60 cells were determined after the indicated period.

MTT Assay
Fludarabine monophosphate was obtained from
Schering AG, Germany. The drug was diluted in a culture
medium and dose-dependent cytotoxic effects were
studied by culturing cells with 0.5–1000 µg/ml
fludarabine monophosphate. MTT assay was used to
evaluate cell viability after drug exposure. Briefly, 50 µl
of cell suspension was seeded in 96-well plates and 50 µl
of drug added to each well. After 48 h of incubation, 25
µl of MTT solution (1 mg/ml final concentration) was
added to each well and the plates were incubated for a
further 4 h. The produced formazan was solubilized by

adding 80 µl of lysing buffer of 23% SDS dissolved in a
solution of 45% DMF (pH 4.7). After an overnight
incubation at 37 °C, the optical densities (OD) at a
wavelength of 540 nm were measured using the
microplate reader (Spectramax Plus, Molecular Devices,
UK). Cells incubated in culture medium alone served as a
control for cell viability (untreated wells). All assays were
performed in quadriplicate and mean ± SD values were
used to estimate inhibition rate. The inhibition rate (% of
cell death) was calculated as (1 - OD of treated cells/OD
of untreated cells) x 100.

Results
Cytotoxicity of Fludarabine on HL60 Cells
The dose-response curve of fludarabine on HL60 cells
is presented in Figure 1. The dose of 5 µg/ml of
fludarabine produced 57% cell death in tumor cells. At
increasing doses, cell viability decreased slightly and a
plateau phase occurred on the drug-response curve. The
percentage of cell death was 69% at the dose of 20 µg/ml
and it did not exceed 71% at the highest dose.

Cytotoxicity of Fludarabine on Differentiated HL60
Cells
The cytotoxic effect of fludarabine on differentiated
HL60 cells is presented in Figures 2 and 3. The dose of 5
µg/ml of fludarabine produced only 5% cell death in these
cells. There was a moderate effect of the drug at the dose
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Figure 1. Cytotoxicity of fludarabine on HL60 cells.
OD values represent mean ± SD of 4 wells.
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Figure 2. Cytotoxicity of fludarabine (1-20 µg/ml) on differentiated HL60 cells.
OD values represent mean ± SD of 4 wells.
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Figure 3. Cytotoxicity of fludarabine (50-800 µg/ml) on differentiated HL60 cells.
OD values represent mean ± SD of 4 wells.

of 50 µg/ml, which was estimated as 20% cell death. The
differentiated HL60 cells failed to reach 50% inhibition
rate at increasing doses. The percentage of cell death was
only 42% at the dose of 800 µg/ml.

Cytotoxicity of
Mononuclear Cells

Fludarabine

on

Normal

The cytotoxic effect of the drug on normal
mononuclear cells is presented in Figures 4 and 5.
Fludarabine did not produce an obvious cytotoxicity in a
dose-dependent manner on normal cells. Both doses of 5
µg/ml and 50 µg/ml of the drug produced 22% cell death.

The percentages of cell death at the doses of 500 µg/ml
and 1000 µg/ml were 33% and 37%, respectively.

Discussion
This study addresses the dose-dependent cytotoxicity
of fludarabine in cells of different origin and/or
maturation state. Fludarabine has a cell cycle specific
cytotoxic effect targeted at DNA synthesis, which
accounts for the killing of dividing cells. Here, we report
cytotoxic effects of the drug on proliferating HL60 cells
and the differentiated subline. It has been reported that
induction to differentiation in immature myeloid cells
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Figure 4. Cytotoxicity of fludarabine (0.5 -100 µg/ml) on normal mononuclear cells.
OD values represent mean ± SD of 4 wells.
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Figure 5. Cytotoxicity of fludarabine (100 -1000 µg/ml) on normal mononuclear cells.
OD values represent mean ± SD of 4 wells.

increases coinciding with a decrease in proliferation rate
(13). In our study, the proliferation rate of HL60 cells
was 3-fold higher than that of differentiated HL60 cells.
The decreased proliferation rate of differentiated HL60
cells was in accordance with this switch in the cycle.
Dimethylformamide induces differentiation in less than
60% of HL60 cells at 96 h (15). It was also shown that,
in culture conditions containing 10% fetal bovine serum
differentiation rate into neutrophils did not exceed 40%
in myeloid cells (13). In our experiments, the
morphologic evaluation (granule content and cell size) on
flow cytometry showed that the differentiation rate was
30%. It is noteworthy that even at low ratios of
230

differentiated cells, insensitivity to the drug was
demonstrated.
We tested the fludarabine dose-response curve, which
included the clinically effective plasma drug levels (17).
Accordingly, at the dose of 5 µg/ml, more than 50% cell
death was achieved in undifferentiated HL60 cells.
Additionally, in freshly isolated tumor cells obtained from
a CLL patient, the cell death was 43% at the same dose.
The percentage of cell death reached 69% at the dose of
50 µg/ml (data not shown). A concordance between doseresponse curves of undifferentiated HL60 cells and the
patient’s leukocytes is evident. These results may be
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critical with respect to the cell specificity and to the
cytotoxicity of the drug at low doses in tumor cells. The
efficiency in lymphoid cells confirms the importance of
fludarabine as being the gold standard in chemotherapy.
González-Cid et al. have shown that fludarabine
induces apoptosis in normal human lymphocytes in a
dose-dependent manner and the apoptotic index has been
found below 20% at 5 µg/ml of drug concentration (18).
We showed that normal mononuclear cells were resistant
to the cytotoxicity of fludarabine even at a dose of 1000
µg/ml.
Deoxycytidine kinase is the dominant kinase for
phosphorylation and activation of fludarabine (3,19). It
has been reported that plasma deoxycytidine levels
increased after chemotherapy. Consecutively, it causes
inhibition of deoxycytidine kinase activity resulting in
decreased fludarabine cytotoxicity (20). In the same
study, HL60 cells treated with fludarabine (10 µM; ~3
µg/ml) and deoxycytidine (0.1-32.4 µM) were shown to
survive in a dose-dependent manner where exposure to

deoxycytidine alone did not affect cell proliferation or
viability. Therefore, it seems likely that the initial poor
activity of fludarabine against either differentiated HL60
cells or normal lymphocytes could not be attributed to
failure of drug activation.
In conclusion, (i) the impact of tumor cell proliferation
rate is critical for the extent of dose-dependent
fludarabine cytotoxicity; (ii) differentiation to mature
phenotype is associated with fludarabine insensitivity, and
(iii) insensitivity to the drug in normal and non-dividing
lymphoid cells should be taken into consideration when
studying drug effects on leukocytes.
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